Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;43:452-459
Published online before print December 29, 2003, doi: 10.1161/01.HYP.0000110905.29389.e5
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/2/452    most recent
01.HYP.0000110905.29389.e5v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xia, C.-F.
Right arrow Articles by Chao, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xia, C.-F.
Right arrow Articles by Chao, J.

(Hypertension. 2004;43:452.)
© 2004 American Heart Association, Inc.


Scientific Contribution

Kallikrein Gene Transfer Protects Against Ischemic Stroke by Promoting Glial Cell Migration and Inhibiting Apoptosis

Chun-Fang Xia; Hang Yin; Cesar V. Borlongan; Lee Chao; Julie Chao

From the Department of Biochemistry and Molecular Biology (C.-F.X., H.Y., L.C., J.C.), Medical University of South Carolina, Charleston, and the Department of Neurology and Institute of Molecular Medicine and Genetics (C.V.B.), Medical College of Georgia, Augusta.

Correspondence to Julie Chao, PhD, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC 29425. E-mail chaoj{at}musc.edu

Kallikrein/kinin has been shown to protect against ischemia/reperfusion-induced myocardial infarction and apoptosis. In the present study, we examined the potential neuroprotective action of kallikrein gene transfer in cerebral ischemia. Adult, male Sprague-Dawley rats were subjected to a 1-hour occlusion of the middle cerebral artery followed by intracerebroventricular injection of adenovirus harboring either the human tissue kallikrein gene or the luciferase gene. Kallikrein gene transfer significantly reduced ischemia-induced locomotor deficit scores and cerebral infarction after cerebral ischemia injury. Expression of recombinant human tissue kallikrein was identified and localized in monocytes/macrophages of rat ischemic brain by double immunostaining. Morphological analyses showed that kallikrein gene transfer enhanced the survival and migration of glial cells into the ischemic penumbra and core, as identified by immunostaining with glial fibrillary acidic protein. Cerebral ischemia markedly increased apoptotic cells, and kallikrein gene delivery reduced apoptosis to near-normal levels as seen in sham control rats. In primary cultured glial cells, kinin stimulated cell migration but inhibited hypoxia/reoxygenation-induced apoptosis in a dose-dependent manner. The effects of kinin on both migration and apoptosis were abolished by icatibant, a bradykinin B2 receptor antagonist. Enhanced cell survival after kallikrein gene transfer occurred in conjunction with markedly increased cerebral nitric oxide levels and phospho-Akt and Bcl-2 levels but reduced caspase-3 activation, NAD(P)H oxidase activity, and superoxide production. These results indicate that kallikrein gene transfer provides neuroprotection against cerebral ischemia injury by enhancing glial cell survival and migration and inhibiting apoptosis through suppression of oxidative stress and activation of the Akt–Bcl-2 signaling pathway.


Key Words: ischemia • stroke • kinins • gene transfer • apoptosis




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Kakoki, R. W. McGarrah, H.-S. Kim, and O. Smithies
Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury
PNAS, May 1, 2007; 104(18): 7576 - 7581.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Chao, H.-J. Li, Y.-Y. Yao, B. Shen, L. Gao, G. Bledsoe, and L. Chao
Kinin Infusion Prevents Renal Inflammation, Apoptosis, and Fibrosis via Inhibition of Oxidative Stress and Mitogen-Activated Protein Kinase Activity
Hypertension, March 1, 2007; 49(3): 490 - 497.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Storini, L. Bergamaschini, R. Gesuete, E. Rossi, D. Maiocchi, and M. G. De Simoni
Selective Inhibition of Plasma Kallikrein Protects Brain from Reperfusion Injury
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 849 - 854.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C.-F. Xia, R. S. Smith Jr, B. Shen, Z.-R. Yang, C. V. Borlongan, L. Chao, and J. Chao
Postischemic Brain Injury Is Exacerbated in Mice Lacking the Kinin B2 Receptor
Hypertension, April 1, 2006; 47(4): 752 - 761.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
J. Chao and L. Chao
Kallikrein-kinin in stroke, cardiovascular and renal disease
Exp Physiol, May 1, 2005; 90(3): 291 - 298.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Yin, L. Chao, and J. Chao
Kallikrein/Kinin Protects against Myocardial Apoptosis after Ischemia/Reperfusion via Akt-Glycogen Synthase Kinase-3 and Akt-Bad{middle dot}14-3-3 Signaling Pathways
J. Biol. Chem., March 4, 2005; 280(9): 8022 - 8030.
[Abstract] [Full Text] [PDF]